Application Note

Meet Your Lentiviral Vector Development And Supply Requirements With An Optimized Suspension-Based Platform Technology

Source: Lonza

By Lisa Prendergast, Licensing, and Bingnan Gu, Research & Development

Scientist Using Computer In Lab GettyImages-1370154322

Demand for lentiviral vectors (LVVs) as delivery vehicles for gene therapies is rising significantly, creating a need for robust, highly productive and scalable manufacturing processes. Lonza's ready-to-use, suspension-based Xcite® Lenti Platform Technology for transient transfection of LVVs eliminates that need to transition from small-scale adherent processes, shortening timelines to GMP production and providing confidence that LVV production processes will be suitable for large-scale manufacturing.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma